Nora Therapeutics to Present at 26th Annual ROTH Conference
PALO ALTO, Calif., March 4, 2014 /PRNewswire/ -- Nora Therapeutics, a biotechnology company focused on developing therapeutics to address unmet needs in reproductive medicine, announced today that CEO Jeffrey K. Tong, Ph.D., is scheduled to present at the 26th Annual ROTH Conference at the Ritz-Carlton in Laguna Niguel, CA, on Monday, March 10, 2014 at 4:15 p.m. PDT.
About Nora Therapeutics, Inc.
Nora Therapeutics is a privately-held biotechnology company focused on developing therapeutics to address IVF failure and recurrent pregnancy loss, two reproductive conditions with significant unmet need. Nora's lead compound, NT100, is a novel biologic agent similar to a naturally occurring protein in the female reproductive tract and may better enable embryo implantation and pregnancy maintenance by optimizing maternal-fetal immune tolerance. For more information, please visit our website at www.noratherapeutics.com.
SOURCE Nora Therapeutics